What is Entresto?
What is Entresto? , it sounds like a Superhero Comic character, formally called LCZ696 is a blockbuster success but only time will tell. The biggest challenge for Novartis, the Swiss based company will be to convince healthcare professionals to move people off “cheap generics” which have been the mainstay of heart failure therapy for many years. Will the young pretender to the crown of “Gold Standard therapy” make it? well only time will tell. As we live in an evidence based medical society Entresto has a great deal of evidence built via the PARADIGM HF trial as to why it is seen and has demonstrated blockbusting qualities that most other condition areas would only dream of.
What is Entresto? the medical bit
Entresto is a first in class medicine (an ARNI, Angiotensin Receptor Neprilysin Inhibitor) that reduces the strain on the failing heart. A twice-a-day tablet, it acts to enhance the protective neurohormonal systems of the heart (NP system) while simultaneously suppressing the harmful system (the RAAS).
Results from the 8,442 patient PARADIGM-HF study showed, versus enalapril, Entresto:
– reduced the risk of death from cardiovascular causes by 20%
– reduced heart failure hospitalizations by 21%
– reduced the risk of all-cause mortality by 16%
Overall there was a 20% risk reduction on the primary endpoint, a composite measure of cardiovascular death or time to first heart failure hospitalisation.
Fewer patients on Entresto discontinued study medication for any adverse event compared to those on enalapril. The Entresto group had more hypotension and non-serious angioedema but less renal impairment, hyperkalemia and cough than the enalapril group.
We hope that this will be the start of new therapeutic developments in heart failure which has historically been the “Cinderella” of the bunch.